文献速递胸部肿瘤

揭示非小细胞肺癌中少见EGFR突变的全貌——一项系统综述

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
PubMed 文献 · J Thorac Oncol · 2024-03-16

该系统综述纳入38项研究共1836例携带少见EGFR突变(除外20号外显子插入突变和T790M)的非小细胞肺癌患者,评估不同代酪氨酸激酶抑制剂的疗效。多数数据(92.6%)来自第一或第二代TKI治疗的患者。G719X、S768I、E709X、L747X和E709-T710delinsD对第二代TKI的缓解率范围为47.8%至72.3%,通常高于第一或第三代TKI;L861Q对第三代TKI的缓解率为75%(95%CI:56.6%-88.5%)。

要点

  • G719X、S768I、E709X、L747X和E709-T710delinsD对第二代TKI的缓解率范围为47.8%至72.3%,通常高于第一或第三代TKI。
  • L861Q对第三代TKI的缓解率为75%(95%CI:56.6%-88.5%)。
  • 该系统综述支持第二代TKI阿法替尼用于G719X、S768I、E709X和L747X突变及复合少见突变;对于L861Q等其他少见突变,第三代TKI如奥希替尼也可考虑。

核心结论

  • 该系统综述支持第二代TKI阿法替尼用于G719X、S768I、E709X和L747X突变以及复合少见突变。
  • 对于L861Q等其他少见突变,鉴于其活性和毒性特征,第三代TKI如奥希替尼也可考虑。

研究设计与样本

  • 该系统综述按照2009年系统综述和Meta分析优先报告条目指南进行。
  • 最终分析纳入38项研究的1836例患者。
  • 少见EGFR突变定义为除外20号外显子插入突变或T790M的突变。
  • 多数可用数据(92.6%)来自接受第一或第二代TKI治疗的患者。

主要发现

  • G719X、S768I、E709X、L747X和E709-T710delinsD对第二代TKI的缓解率范围为47.8%至72.3%,通常高于第一或第三代TKI。
  • L861Q突变对第三代TKI的缓解率为75%(95%CI:56.6%-88.5%)。
  • 含G719X、E709X或S768I的复合突变对第二代和第三代TKI的缓解率始终高于50%,但第三代TKI数据较少。
  • 经典样突变对第一、第二和第三代TKI的缓解率分别为35.4%(95%CI:27.2%-44.2%)、51.9%(95%CI:44.4%-59.3%)和67.9%(95%CI:47.6%-84.1%)。
  • P-loop α螺旋压缩类突变对第一、第二和第三代TKI的缓解率分别为37.2%(95%CI:32.4%-42.1%)、59.6%(95%CI:54.8%-64.3%)和46.3%(95%CI:32.6%-60.4%)。

关键数值与推荐

  • G719X、S768I、E709X、L747X和E709-T710delinsD对第二代TKI的缓解率范围为47.8%至72.3%。
  • L861Q对第三代TKI的缓解率为75%(95%CI:56.6%-88.5%)。
  • 经典样突变对第一、第二和第三代TKI的缓解率分别为35.4%(95%CI:27.2%-44.2%)、51.9%(95%CI:44.4%-59.3%)和67.9%(95%CI:47.6%-84.1%)。
  • P-loop α螺旋压缩类突变对第一、第二和第三代TKI的缓解率分别为37.2%(95%CI:32.4%-42.1%)、59.6%(95%CI:54.8%-64.3%)和46.3%(95%CI:32.6%-60.4%)。

临床怎么用

  • 该系统综述支持第二代TKI阿法替尼用于G719X、S768I、E709X和L747X突变以及复合少见突变。
  • 对于L861Q等其他少见突变,第三代TKI如奥希替尼也可考虑,鉴于其活性和毒性特征。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uncommon EGFR mutations represent a rare subgroup of NSCLC. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations are scattered and limited to mostly retrospective small cohorts because these patients were usually excluded from clinical trials. This was a systematic review on the efficacy of TKIs in patients harboring uncommon EGFR mutations, defined as mutations other than exon 20 insertions mutations or T790M. Response rates (RRs) for different generations of TKIs were determined for individual uncommon mutations, compound mutations, and according to classical-like and P-loop alpha helix compressing mutations classes. This study was conducted in accordance with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A total of 1836 patients from 38 studies were included in the final analysis. Most available data (92.6%) were from patients treated with first- or second-generation TKIs. G719X, S768I, E709X, L747X, and E709-T710delinsD showed RRs ranging from 47.8% to 72.3% to second-generation TKIs, generally higher than for first- or third-generation TKIs. L861Q mutation exhibited 75% (95% confidence interval [CI]: 56.6%-88.5%) RRs to third-generation TKIs. Compound mutations with G719X, E709X, or S768I consistently showed RRs above 50% to second- and third-generation TKIs, although fewer data were available for third generations. For classical-like mutations, RRs were 35.4% (95% CI: 27.2%-44.2%), 51.9% (95% CI: 44.4%-59.3%), and 67.9% (95% CI: 47.6%-84.1%) to first-, second-, and third-generation TKIs, whereas for P-loop alpha helix compressing mutations classes mutations, RRs were 37.2% (95% CI: 32.4%-42.1%), 59.6% (95% CI: 54.8%-64.3%), and 46.3% (95% CI: 32.6%-60.4%), respectively. This systematic review supports the use of second-generation TKI afatinib for G719X, S768I, E709X, and L747X mutations and for compound uncommon mutations. For other uncommon mutations such as L861Q, third-generation TKI, such as osimertinib, could also be considered, given its activity and toxicity profile.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Borgeaud M, Parikh K, Banna GL, et al. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. J Thorac Oncol. 2024. PMID: 38499147. doi:10.1016/j.jtho.2024.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。